Latest Licensing News

Krakatoa Resources has kicked off its 2026 drilling campaign at the Zopkhito Project in Georgia, aiming to convert a significant foreign resource estimate into a JORC-compliant Mineral Resource Estimate while advancing early mine development studies.

Canyon Resources hits a key logistics milestone with locomotive delivery in Cameroon and prepares for trial mining at its Minim Martap bauxite project, targeting first shipments by year-end.

Chilwa Minerals has identified widespread rare earth element mineralisation in clays directly beneath its Mposa heavy mineral sands deposit in Malawi, revealing potential for a dual-commodity mining operation pending metallurgical test results.

Flagship Minerals has agreed to sell its RK Lithium Project in Thailand for US$4 million, accelerating its strategic pivot towards gold and copper assets in Chile and Canada.

Mesoblast has drawn US$50 million from a new five-year facility that reduces its interest burden and retires expensive short-term debt, strengthening its financial position ahead of commercial expansion.

Aldoro Resources has hit a new high-water mark at its Kameelburg project with drill hole DD008F delivering the thickest and highest-grade rare earth mineralisation to date. The full Phase II assay suite confirms a vast, multi-commodity system and an imminent resource update.

Vinyl Group has completed its acquisition of Time Out Australia, securing exclusive rights to the brand and expanding its media reach across digital and events platforms.

Livium is positioning its Envirostream subsidiary to capitalise on the growing battery recycling needs from Australia's booming AI data centre sector, leveraging its EPA-licensed facilities and national network.

Ramelius Resources secures a key environmental nod from WA EPA, clearing the Roe Project to advance via a streamlined Part V approval process and setting the stage for early works in late 2026.

Provaris Energy has hit a major FEED milestone, submitting its detailed engineering package for the YP-Provaris LCO2 tank to DNV for maritime certification, positioning the company for significant CCS supply chain opportunities.

AFT Pharmaceuticals surged 22% to NZ$254.7 million revenue in FY26, surpassing profit guidance and securing FDA approval to advance a pivotal injectable iron Phase III trial targeting a $7.4 billion market. The company is poised for further global expansion and product launches in FY27.

AFT Pharmaceuticals delivered a 22% revenue jump in FY26 to NZD 254.7 million, surpassing profit guidance and expanding its footprint to 87 countries. The company is advancing multiple R&D projects, including a pivotal Phase III injectable iron trial, while targeting over NZD 300 million in revenue for FY27.